ALB and neoplasm: We innovatively fused an antihuman serum albumin nanobody to a single‐domain antibody–drug conjugates targeting oncofetal antigen 5T4, conferring serum albumin binding, exhibiting a 10‐fold extended half‐life and enhanced tumor accumulation and retention in mice.